Rice Hall James & Associates LLC Sells 6,878 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

Rice Hall James & Associates LLC reduced its stake in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) by 1.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 642,752 shares of the company’s stock after selling 6,878 shares during the period. Rice Hall James & Associates LLC owned 0.89% of Kiniksa Pharmaceuticals worth $12,714,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in the stock. Peregrine Capital Management LLC grew its stake in Kiniksa Pharmaceuticals by 1.8% in the 4th quarter. Peregrine Capital Management LLC now owns 244,043 shares of the company’s stock worth $4,827,000 after acquiring an additional 4,361 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its stake in Kiniksa Pharmaceuticals by 12.9% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,814 shares of the company’s stock worth $174,000 after acquiring an additional 1,004 shares in the last quarter. SG Americas Securities LLC bought a new position in Kiniksa Pharmaceuticals in the 4th quarter worth about $355,000. Hennion & Walsh Asset Management Inc. grew its stake in Kiniksa Pharmaceuticals by 1.9% in the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 199,525 shares of the company’s stock worth $3,947,000 after acquiring an additional 3,673 shares in the last quarter. Finally, Nordea Investment Management AB boosted its stake in shares of Kiniksa Pharmaceuticals by 4.4% during the fourth quarter. Nordea Investment Management AB now owns 194,883 shares of the company’s stock valued at $3,818,000 after purchasing an additional 8,257 shares in the last quarter. 53.95% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

KNSA has been the topic of a number of recent research reports. Evercore ISI increased their price objective on shares of Kiniksa Pharmaceuticals from $30.00 to $35.00 and gave the company an “outperform” rating in a research note on Wednesday, October 30th. Wedbush reiterated an “outperform” rating and set a $34.00 price objective on shares of Kiniksa Pharmaceuticals in a research note on Monday, January 13th. Finally, JPMorgan Chase & Co. increased their price objective on shares of Kiniksa Pharmaceuticals from $39.00 to $40.00 and gave the company an “overweight” rating in a research note on Tuesday, November 5th. Five analysts have rated the stock with a buy rating, According to MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $36.60.

Insider Activity at Kiniksa Pharmaceuticals

In related news, CFO Mark Ragosa sold 8,969 shares of the stock in a transaction that occurred on Tuesday, December 3rd. The shares were sold at an average price of $21.45, for a total transaction of $192,385.05. Following the completion of the sale, the chief financial officer now owns 22,958 shares of the company’s stock, valued at $492,449.10. This represents a 28.09 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, COO Eben Tessari sold 14,000 shares of the firm’s stock in a transaction on Monday, February 10th. The stock was sold at an average price of $19.57, for a total transaction of $273,980.00. Following the completion of the transaction, the chief operating officer now directly owns 81,975 shares of the company’s stock, valued at approximately $1,604,250.75. This represents a 14.59 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 38,092 shares of company stock valued at $745,589 over the last 90 days. Insiders own 54.57% of the company’s stock.

Kiniksa Pharmaceuticals Price Performance

NASDAQ:KNSA opened at $19.74 on Tuesday. Kiniksa Pharmaceuticals, Ltd. has a 52 week low of $16.56 and a 52 week high of $28.15. The firm has a 50 day moving average of $19.79 and a 200 day moving average of $22.80.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.